202 related articles for article (PubMed ID: 31254304)
1. The efficacy and safety of hypofractionated radiotherapy with concurrent anti-HER-2 therapy following breast-conserving therapy for breast cancer.
Dreyfuss AD; Barsky AR; Taunk NK; Clark AS; Freedman GM
Breast J; 2019 Nov; 25(6):1097-1103. PubMed ID: 31254304
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Outcomes Using Hypofractionated Tumor Bed Boost Combined With Hypofractionated Whole Breast Irradiation for Early-stage Breast Cancer.
Yu E; Huang D; Leonard K; Dipetrillo T; Wazer D; Hepel J
Clin Breast Cancer; 2017 Dec; 17(8):638-643. PubMed ID: 28629952
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
4. Short-Course Hypofractionated Radiation Therapy With Boost in Women With Stages 0 to IIIa Breast Cancer: A Phase 2 Trial.
Ahlawat S; Haffty BG; Goyal S; Kearney T; Kirstein L; Chen C; Moore DF; Khan AJ
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):118-125. PubMed ID: 26700706
[TBL] [Abstract][Full Text] [Related]
5. [Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity].
Ben Dhia S; Loap P; Loirat D; Vincent-Salomon A; Cao K; Escalup L; Fourquet A; Kirova Y
Cancer Radiother; 2021 Jul; 25(5):424-431. PubMed ID: 33771453
[TBL] [Abstract][Full Text] [Related]
6. [Preliminary results of whole breast helical tomotherapy with simultaneous integrated boost in the adjuvant treatment of breast cancer].
Liem X; Chira C; Fourquet A; Campana F; Peurien D; Fournier-Bidoz N; Kirova YM
Cancer Radiother; 2014 Jan; 18(1):15-22. PubMed ID: 24316350
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis.
Dong J; Yang Y; Han D; Zhao Q; Liu C; Sun H; Wang Z; Lin H; Huang W
Technol Cancer Res Treat; 2021; 20():15330338211064719. PubMed ID: 34898315
[No Abstract] [Full Text] [Related]
8. An accelerated hypofractionated schedule with a daily concomitant boost after breast conservation surgery: the feasibility and toxicity.
Ghannam AA; Khedr RA
J Egypt Natl Canc Inst; 2016 Mar; 28(1):39-44. PubMed ID: 26833225
[TBL] [Abstract][Full Text] [Related]
9. A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects.
Guenzi M; Vagge S; Azinwi NC; D'Alonzo A; Belgioia L; Garelli S; Gusinu M; Corvò R
Radiat Oncol; 2010 Nov; 5():111. PubMed ID: 21092219
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated radiotherapy for breast cancers--preliminary results from a tertiary care center in eastern India.
Nandi M; Mahata A; Mallick I; Achari R; Chatterjee S
Asian Pac J Cancer Prev; 2014; 15(6):2505-10. PubMed ID: 24761855
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated whole breast radiotherapy with or without hypofractionated boost in early stage breast cancer patients: a mono-institutional analysis of skin and subcutaneous toxicity.
Palumbo I; Mariucci C; Falcinelli L; Perrucci E; Lancellotta V; Podlesko AM; Marcantonini M; Saldi S; Bini V; Aristei C
Breast Cancer; 2019 May; 26(3):290-304. PubMed ID: 30341747
[TBL] [Abstract][Full Text] [Related]
12. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
[TBL] [Abstract][Full Text] [Related]
13. Ten-year results of accelerated hypofractionated adjuvant whole-breast radiation with concomitant boost to the lumpectomy cavity after conserving surgery for early breast cancer.
Cante D; Petrucci E; Sciacero P; Piva C; Ferrario S; Bagnera S; Patania S; Mondini G; Pasquino M; Casanova Borca V; Vellani G; La Porta MR; Franco P
Med Oncol; 2017 Sep; 34(9):152. PubMed ID: 28776318
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors.
Ciammella P; Podgornii A; Galeandro M; Micera R; Ramundo D; Palmieri T; Cagni E; Iotti C
Radiat Oncol; 2014 Apr; 9():97. PubMed ID: 24762173
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated Breast Radiation: Shorter Scheme, Lower Toxicity.
Linares I; Tovar MI; Zurita M; Guerrero R; Expósito M; Del Moral R
Clin Breast Cancer; 2016 Aug; 16(4):262-8. PubMed ID: 26454613
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2 Study of 2 Weeks of Adjuvant Whole Breast/Chest Wall and/or Regional Nodal Radiation Therapy for Patients With Breast Cancer.
Yadav BS; Sharma SC
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):874-881. PubMed ID: 29485066
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionation with no boost after breast conservation in early-stage breast cancer patients.
Arcadipane F; Franco P; De Colle C; Rondi N; Di Muzio J; Pelle E; Martini S; Ala A; Airoldi M; Donadio M; De Sanctis C; Castellano I; Ragona R; Ricardi U
Med Oncol; 2016 Oct; 33(10):108. PubMed ID: 27573380
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
19. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial.
Shaitelman SF; Schlembach PJ; Arzu I; Ballo M; Bloom ES; Buchholz D; Chronowski GM; Dvorak T; Grade E; Hoffman KE; Kelly P; Ludwig M; Perkins GH; Reed V; Shah S; Stauder MC; Strom EA; Tereffe W; Woodward WA; Ensor J; Baumann D; Thompson AM; Amaya D; Davis T; Guerra W; Hamblin L; Hortobagyi G; Hunt KK; Buchholz TA; Smith BD
JAMA Oncol; 2015 Oct; 1(7):931-41. PubMed ID: 26247543
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
